In today’s session Ariad Pharmaceuticals, Inc. (ARIA) registered an unusually high (1,530) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious ARIA increase. With 1,530 contracts traded and 3364 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: ARIA161021C00013500 closed last at: $0.45 or 12.5% up. About 6.71M shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 72.45% since March 14, 2016 and is uptrending. It has outperformed by 66.83% the S&P500.
Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on November, 1. They expect $-0.20 earnings per share, up 31.03% or $0.09 from last year’s $-0.29 per share. After $0.57 actual earnings per share reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -135.09% negative EPS growth.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 5 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. Ariad Pharmaceuticals has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Friday, August 7 by JP Morgan. The rating was maintained by Barclays Capital with “Underweight” on Wednesday, May 11. As per Monday, September 26, the company rating was initiated by Leerink Swann. The firm earned “Buy” rating on Wednesday, October 5 by Suntrust Robinson. The firm earned “Underweight” rating on Tuesday, January 19 by Barclays Capital. The rating was initiated by SunTrust on Wednesday, October 5 with “Buy”. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The company was maintained on Friday, July 29 by Barclays Capital.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.73, from 0.67 in 2016Q1. The ratio improved, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Blackrock Japan has 0% invested in the company for 1,282 shares. Oxford Asset Management last reported 0.23% of its portfolio in the stock. Art Lc accumulated 0.16% or 438,817 shares. Creative Planning has 0% invested in the company for 29,000 shares. Hsbc Public Limited Liability Co, a United Kingdom-based fund reported 613 shares. The Illinois-based Spot Trading Ltd Llc has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Tekla Cap Mngmt accumulated 502,000 shares or 0.15% of the stock. California State Teachers Retirement Sys last reported 371,038 shares in the company. Walleye Trading Ltd Liability Co accumulated 0% or 500 shares. Pointstate Capital L P accumulated 3.80M shares or 0.58% of the stock. Panagora Asset Mgmt has 29,994 shares for 0% of their US portfolio. Credit Suisse Ag last reported 0% of its portfolio in the stock. Westfield Cap Mngmt Limited Partnership holds 0.64% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 10.58 million shares. The Massachusetts-based Camber Capital Mgmt Limited Liability Corp has invested 1.43% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). The Ontario – Canada-based Royal State Bank Of Canada has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).
Insider Transactions: Since April 22, 2016, the stock had 1 insider buy, and 12 insider sales for $3.87 million net activity. $148,230 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares were sold by CLACKSON TIMOTHY P. Another trade for 108,569 shares valued at $896,135 was made by Radaelli Massimo on Friday, June 10. Another trade for 26,990 shares valued at $199,996 was made by Panayiotopoulos Paris on Thursday, May 12. 76,250 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $626,039 were sold by LAVIDAS ATHANESE.
ARIAD Pharmaceuticals, Inc. is an oncology company. The company has a market cap of $1.87 billion. The Firm is focused on transforming the lives of cancer patients with medicines. It currently has negative earnings. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Prnewswire.com, which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 07, 2016. Prnewswire.com‘s article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” and published on October 07, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.